Drug intelligence / Profile preview

SyB L-0501 + rituximab

Development stage: Unknown
Lead developer: SymBio Pharmaceuticals
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

Combination of **SyB L-0501** (bendamustine, a bifunctional alkylating agent active in lymphoid cancers) and **rituximab** (a monoclonal antibody targeting CD20 on B cells). Intended for the treatment of aggressive B-cell non-Hodgkin's lymphoma and relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Bendamustine cross-links DNA, causing apoptosis in malignant cells; rituximab binds CD20, mediating B-cell depletion via immune mechanisms. Developed by SymBio Pharmaceuticals, the regimen has advanced to phase III clinical trials for DLBCL and completed extensive evaluation in phase I/II trials[1][4][6][7][10].

Targets

CD20 (B-lymphocyte antigen CD20)DNA

Beyond the preview

Go deeper on SyB L-0501 + rituximab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SyB L-0501 + rituximab.

Explore the full profile